Anti-CD20 monoclonal antibodies: reviewing a revolution

被引：66
|
作者：
Casan, J. M. L. [1 ]
Wong, J. [1 ]
Northcott, M. J. [2 ,3 ]
Opat, S. [1 ,3 ]
机构：
[1] Monash Hlth, Haematol Dept, Melbourne, Vic, Australia
[2] Monash Hlth, Rheumatol Dept, Melbourne, Vic, Australia
[3] Monash Univ, Sch Clin Sci, Melbourne, Vic, Australia
来源：
HUMAN VACCINES & IMMUNOTHERAPEUTICS | 2018年 / 14卷 / 12期
关键词：
Monoclonal antibody; CD20; rituximab; obinutuzumab; immunotherapy; lymphoma; CHRONIC LYMPHOCYTIC-LEUKEMIA; B-CELL LYMPHOMA; MULTICENTER PHASE-II; NON-HODGKIN-LYMPHOMA; PREVIOUSLY UNTREATED PATIENTS; ACTIVE RHEUMATOID-ARTHRITIS; REFRACTORY FOLLICULAR LYMPHOMA; RITUXIMAB MAINTENANCE IMPROVES; SYSTEMIC-LUPUS-ERYTHEMATOSUS; CHEMOTHERAPY PLUS RITUXIMAB;
D O I：
10.1080/21645515.2018.1508624
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
Since the inception of rituximab in the 1990s, anti-CD20 monoclonal antibodies have revolutionised the treatment of B cell hematological malignancies and have become a cornerstone of modern gold-standard practice. Additionally, the potent efficacy of these agents in depleting the B cell compartment has been used in the management of a broad array of autoimmune diseases. Multiple iterations of these agents have been investigated and are routinely used in clinical practice. In this review, we will discuss the physiology of CD20 and its attractiveness as a therapeutic target, as well as the pharmacology, pre-clinical and clinical data for the major anti-CD20 monoclonal antibodies: rituximab, obinutuzumab and ofatumumab.
引用
收藏
页码：2820 / 2841
页数：22
相关论文
共 50 条
  • [41] Multiple signaling pathways of hexavalent anti-CD20 and hexavalent, bispecific, anti-CD20/CD22 humanized monoclonal antibodies correlate with improved anti-lymphoma properties
    Gupta, Pankaj
    Goldenberg, David
    Chang, Chien-Hsing
    CANCER RESEARCH, 2009, 69
  • [42] Switching from natalizumab to anti-CD20 monoclonal antibodies: optimal timing and safety analysis
    Levin, S.
    Levine, L.
    Vargas, W.
    Straus-Farber, R.
    De Jager, P.
    Riley, C.
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 333 - 333
  • [43] Systematic literature review of immunoglobulin trends for anti-CD20 monoclonal antibodies in multiple sclerosis
    Shiv Saidha
    Judith Bell
    Sydney Harold
    Jose Marcano Belisario
    Emma Hawe
    Qiujun Shao
    Kerri Wyse
    Eric M. Maiese
    Neurological Sciences, 2023, 44 : 1515 - 1532
  • [44] Key characteristics of anti-CD20 monoclonal antibodies and clinical implications for multiple sclerosis treatment
    Delgado, Silvia R.
    Faissner, Simon
    Linker, Ralf A.
    Rammohan, Kottil
    JOURNAL OF NEUROLOGY, 2024, 271 (04) : 1515 - 1535
  • [45] Long-term treatment with anti-CD20 monoclonal antibodies is untenable because of risk - No
    Tallantyre, Emma C.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (08) : 1175 - 1177
  • [46] New and Old Anti-CD20 Monoclonal Antibodies for Nephrotic Syndrome. Where We Are?
    Basu, Biswanath
    Angeletti, Andrea
    Islam, Bilkish
    Ghiggeri, Gian Marco
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [47] Treatment of multiple sclerosis with Anti-CD20 antibodies
    Barun, Barbara
    Bar-Or, Amit
    CLINICAL IMMUNOLOGY, 2012, 142 (01) : 31 - 37
  • [48] New Anti-CD20 Monoclonal Antibodies for the Treatment of B-Cell Lymphoid Malignancies
    Robak, Tadeusz
    Robak, Ewa
    BIODRUGS, 2011, 25 (01) : 13 - 25
  • [49] New Anti-CD20 Monoclonal Antibodies for the Treatment of B-Cell Lymphoid Malignancies
    Tadeusz Robak
    Ewa Robak
    BioDrugs, 2011, 25 : 13 - 25
  • [50] Systematic literature review of immunoglobulin trends for anti-CD20 monoclonal antibodies in multiple sclerosis
    Saidha, Shiv
    Bell, Judith
    Harold, Sydney
    Belisario, Jose Marcano
    Hawe, Emma
    Shao, Qiujun
    Wyse, Kerri
    Maiese, Eric M.
    NEUROLOGICAL SCIENCES, 2023, 44 (05) : 1515 - 1532
12345